Patents by Inventor Akio Kanatani
Akio Kanatani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7547693Abstract: Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnnia, repetitive hypersomnnia, true hypersomnnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disType: GrantFiled: September 21, 2004Date of Patent: June 16, 2009Assignee: Banyu Pharmaceutical Co. Ltd.Inventors: Norikazu Ohtake, Ryo Yoshimoto, Shigeru Tokita, Akio Kanatani, Sayaka Mizutani
-
Patent number: 7541477Abstract: This invention relates to a benzimidazole derivative of the general formula [I] [wherein B1, B2, and B3 represent hydrogen atom or lower alkyl; R1 and R2 are same or different and represent lower alkyl, etc.; R3 and R4 represent hydrogen atom, etc.; W represents a 3 to 8-membered aromatic or alphatic heterocycle, etc.; and Ar represents a substituted or unsubstituted aromatic heterocycle, etc.] This compound functions as an antagonist to melanin-concentrating hormone receptor and is useful as a drug for central diseases, circulatory diseases and metabolic diseases.Type: GrantFiled: July 29, 2003Date of Patent: June 2, 2009Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Minoru Moriya, Akio Kanatani, Hisashi Iwaasa, Akane Ishihara, Takehiro Fukami
-
Patent number: 7531668Abstract: A compound represented by the formula [I]: [wherein R1 and R2 are the same or different and each represents C1-6 alkyl, C3-8 cycloalkyl, et al; R3a, R3b, and R4 are the same or different and each represents hydrogen, C1-6 alkyl, et al; X represents —N—, —CH—, et al; Y1 represents a single bond, C1-3 alkylene, et al; Y2 represents C1-4 alkylene, oxy(C1-4 alkylene), et al; Ar1 represents a monocyclic aromatic carbocyclic group, monocyclic aromatic heterocyclic group, et al; and Ar2 represents a 5- or 6-membered aromatic carbocyclic group, aromatic heterocyclic group, et al]. This compound functions as a melanin-concentrating hormone receptor antagonist and is useful as, e.g., a therapeutic agent for obesity, et al.Type: GrantFiled: September 30, 2005Date of Patent: May 12, 2009Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Takao Suzuki, Minoru Moriya, Shunji Sakuraba, Sayaka Mizutani, Hisashi Iwaasa, Akio Kanatani
-
Publication number: 20090105136Abstract: An NPY Y2 agonist is used as a therapeutic agent for a disease accompanied by diarrhea. A compound capable of treating the disease can be evaluated and screened by examining the compound on the targeting to an NPY Y2 receptor. An agent capable of inhibiting the diarrhea by a novel mechanism of action; and a method for evaluation of a compound, including the screening for the agent.Type: ApplicationFiled: June 6, 2006Publication date: April 23, 2009Inventors: Jun Suzuki, Ryuichi Moriya, Hiroyasu Hirose, Akio Kanatani
-
Patent number: 7521455Abstract: The present invention provides a compound represented by formula (I) below, or a pharmaceutically acceptable salt thereof, which, having histamine H3 receptor antagonist or inverse agonist activity, is useful in the prophylaxis or therapy of metabolic diseases, circulatory diseases, or nervous system diseases. [where, for example, Ar is a divalent group formed by eliminating two hydrogen atoms from benzene, X1 is a nitrogen atom, sulfur atom or oxygen atom, R1 is a 5- to 6-membered heteroaryl group, Ring A is a 5- to 6-membered heteroaryl ring, R2 and R3 are amino groups or alkylamino groups, and X2 is represented by formula (II): (where R4 and R5 are lower alkyl groups, and n is an integer from 2 to 4).Type: GrantFiled: February 14, 2005Date of Patent: April 21, 2009Assignee: Banyu Pharmaceutical Co. Ltd.Inventors: Tsuyoshi Nagase, Nagaaki Sato, Akio Kanatani, Shigeru Tokita
-
Patent number: 7510833Abstract: In the examination of obesity or leanness, the examination is based on the expression level of the MCP-1 gene or the MCP-1 protein in a tissue or cell analyte, or on the polymorphism in the gene. In the evaluation of compounds, including screening for therapeutic agents for obesity or leanness, the properties of the MCP-1 gene or the MCP-1 protein are utilized to carry out the evaluation.Type: GrantFiled: March 12, 2004Date of Patent: March 31, 2009Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Hidehito Kotani, Hiraku Itadani, Hiromitsu Araki, Kazuhiko Takahashi, Satoshi Mashiko, Akane Ishihara, Akio Kanatani
-
Patent number: 7504412Abstract: The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R1 and R2 may be the same or different and stand for C1-6 alkyl or the like, R3 and R4 stand for hydrogen atom, methyl group or the like, W stands for mono- or bi-cyclic 3- to 8-membered aromatic or aliphatic heterocycle or the like, and Ar stands for optionally substituted aromatic heterocycle or the like]. These compounds act as melanin-concentrating hormone receptor antagonist and are useful as medicines for central nervous system disorders, cardiovascular system disorders and metabolic disorders.Type: GrantFiled: August 13, 2004Date of Patent: March 17, 2009Assignee: Banyu Pharmaceuticals, Co., Ltd.Inventors: Hiroyuki Kishino, Minoru Moriya, Toshihiro Sakamoto, Hidekazu Takahashi, Shunji Sakuraba, Takao Suzuki, Akio Kanatani
-
Patent number: 7485647Abstract: This invention provides 2-aminoquinoline derivatives represented by a general formula [I] [in which R1 and R2 either stand for lower alkyl, lower cycloalkyl, etc., or R1 and R2 together form an aliphatic nitrogen-containing heterocycle with the nitrogen atom to which they bind; R3, R4, R5, R6 and R7 stand for hydrogen, lower alkyl, etc.; R8 stands for lower alkyl, lower alkyloxy, etc.; and n stands for an integer of 0-4]. The compounds act as melanin concentrating hormone receptor antagonist, and are useful as medicines for central nervous system disorders, cardiovascular disorders and metabolic disorders.Type: GrantFiled: May 20, 2004Date of Patent: February 3, 2009Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Minoru Moriya, Takao Suzuki, Akane Ishihara, Hisashi Iwaasa, Akio Kanatani
-
Publication number: 20090029406Abstract: The present invention has its object to provide an agent capable of ameliorating the intestinal tract dysfunction through a novel mechanism of action. It also has its object to provide a method for the evaluation of a compound, including the screening of the agent. A disease accompanied by intestinal tract dysfunction can be ameliorated or treated by using an NPY Y4 agonist as a therapeutic agent. A compound capable of ameliorating or treating a disease accompanied by intestinal tract dysfunction can be evaluated or screened by evaluating a compound targeting to an NPY Y4 receptor.Type: ApplicationFiled: February 23, 2007Publication date: January 29, 2009Inventors: Jun Suzuki, Ryuichi Moriya, Hiroyasu Hirose, Tetsuya Kanno, Akio Kanatani
-
Patent number: 7482358Abstract: Compounds represented by the general formula (I): wherein Ar1 and Ar2 are each aryl or heteroaryl; R1 is lower cycloalkyl, —Ar3, or a group of the general formula (a), (b) or (c): and R2 and R3are each hydrogen, lower cycloalkyl, lower alkenyl, or optionally substituted lower alkyl (with the proviso that when R2 and R3 are simultaneously hydrogen, Ar1, Ar2 and R1 do not simultaneously represent unsubstituted phenyl).Type: GrantFiled: February 7, 2006Date of Patent: January 27, 2009Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Nagaaki Sato, Osamu Okamoto, Makoto Jitsuoka, Keita Nagai, Akio Kanatani, Akane Ishihara, Yasuyuki Ishii, Takehiro Fukami
-
Publication number: 20090023163Abstract: It is intended to provide a method of measuring an activity, which is a method of measuring an activity of an enzymatic reaction in which a lipid-soluble reaction product is formed by catalyzing an addition reaction of two or more kinds of substrates, characterized by comprising a labeling step in which any one of the substrates is labeled, a reaction step in which an enzymatic reaction is carried out in the presence of an enzyme, all substrates and an acceptor, and a detection step in which the reaction product is detected by bringing the labeled molecule and a molecule to be detected close to each other via the acceptor and transferring an energy generated by the labeled molecule to the molecule to be detected, and a method of evaluating a compound utilizing the method of measuring an activity.Type: ApplicationFiled: March 29, 2006Publication date: January 22, 2009Inventors: Shigeru Tokita, Ken Shimamura, Yasuhisa Miyamoto, Hidefumi Kitazawa, Akio Kanatani
-
Publication number: 20080275069Abstract: This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R1 represents a lower alkyl group et al; R2 and R3 are same and different and represents hydrogen atm et al; R4 represents the substituent of the formula (I) et al; X1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.Type: ApplicationFiled: May 30, 2005Publication date: November 6, 2008Inventors: Takashi Mizutani, Tsuyoshi Nagase, Nagaaki Sato, Akio Kanatani, Shigeru Tokita
-
Publication number: 20080200494Abstract: The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R1 and R2 may be the same or different and stand for C1-6 alkyl or the like, R3 and R4 stand for hydrogen atom, methyl group or the like, W stands for mono- or bi-cyclic 3- to 8-membered aromatic or aliphatic heterocycle or the like, and Ar stands for optionally substituted aromatic heterocycle or the like]. These compounds act as melanin-concentrating hormone receptor antagonist and are useful as medicines for central nervous system disorders, cardiovascular system disorders and metabolic disorders.Type: ApplicationFiled: August 13, 2004Publication date: August 21, 2008Inventors: Hiroyuki Kishino, Minoru Moriya, Toshihiro Sakamoto, Hidekazu Takahashi, Shunji Sakuraba, Takao Suzuki, Akio Kanatani
-
Publication number: 20080188507Abstract: The present invention relates to a compound of the formula (I): wherein Az is a group comprising a monocyclic azole or a bicyclic aromatic ring of the same or different fused azoles; T, U, V and W are independently methine or nitrogen, said methine being optionally substituted by a substituent, and at least two of T, U, V and W are said methine groups; and X is nitrogen or methine. The compounds of the present invention are useful as agents for the treatment of various kinds of diseases related to NPY, for example, cardiovascular disorders, nervous system disorders, genitative diseases, metabolic diseases, genital or reproductive disorders, gastro-intestinal disorders, respiratory disorders, inflammatory diseases or glaucoma, and the like.Type: ApplicationFiled: February 26, 2008Publication date: August 7, 2008Inventors: Norikazu Otake, Yuji Haga, Makoto Jitsuoka, Akio Kanatani
-
Publication number: 20080161326Abstract: The present invention relates to compounds of the general formula (I): wherein A, B, C and D each independently are a methine group or a nitrogen atom, said methine group optionally having a substituent(s) with at least one of them meaning the methine group; E means a group represented by the following formulae (E1): R1 means a lower alkyl group or an aryl group optionally having a substituent(s) or means a lower alkylene group linked to arbitrary, linkable position(s) of E, and others. The compounds of the present invention are useful as an agent for the treatment of a variety of diseases related to NPY.Type: ApplicationFiled: February 15, 2005Publication date: July 3, 2008Inventors: Norikazu Otake, Yoshio Ogino, Akio Kanatani
-
Publication number: 20080139589Abstract: A substance that has a potency antagonistic to coupling of histamine with histamine H3 receptor or a potency of inhibiting the constant activity of histamine H3 receptor. There is provided a form I crystal of 2-methyl 3-{4-[3-(1-pyrrolidinyl)propoxy]phenyl}-5-trifluoromethyl-4(3H)-quinazolinone that in the powder X- ray diffractometry, has peaks at 6.4°, 9.7°, 10.2°, 12.9°, 14.2°, 14.7°, 16.0°, 16.3°, 16.8°, 17.6°, 19.5°, 20.3°, 20.6°, 21.2°, 21.8°, 22.1°, 22.4°, 22.6°, 24.0°, 24.3°, 24.9°, 25.7°, 25.9°, 26.5°, 26.7°, 27.4°, 29.1°, 29.4°, 32.3° and 39.0° diffraction angles(2?±0.2°).Type: ApplicationFiled: February 13, 2006Publication date: June 12, 2008Inventors: Akio Kanatani, Nagaaki Sato, Tsuyoshi Nagase, Shigeru Tokita
-
Publication number: 20080118436Abstract: An object of the present invention is to provide a pathologic model animal more accurately reflecting the pathologic conditions of nonalcoholic steatohepatitis patients, and the present invention provides the pathologic model animal for nonalcoholic steatohepatitis produced by continuously administering a tetracycline antibiotic to an animal having its body weight significantly increased compared with that of a group fed with a normal diet by feeding it with a high-fat diet.Type: ApplicationFiled: September 13, 2005Publication date: May 22, 2008Inventors: Jun Suzuki, Hisashi Iwaasa, Minoru Sasaki, Makoto Ito, Akio Kanatani
-
Patent number: 7365079Abstract: The present invention relates to a compound of the formula (I): wherein Az is a group comprising a monocyclic azole or a bicyclic aromatic ring of the same or different fused azoles; T, U, V and W are independently methine or nitrogen, said methine being optionally substituted by a substituent, and at least two of T, U, V and W are said methine groups; and X is nitrogen or methine. The compounds of the present invention are useful as agents for the treatment of various kinds of diseases related to NPY, for example, cardiovascular disorders, nervous system disorders, genitative diseases, metabolic diseases, genital or reproductive disorders, gastrointestinal disorders, respiratory disorders, inflammatory diseases or glaucoma, and the like.Type: GrantFiled: November 25, 2003Date of Patent: April 29, 2008Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Norikazu Otake, Yuji Haga, Makoto Jitsuoka, Akio Kanatani
-
Publication number: 20070299070Abstract: A compound represented by the formula [I]: [wherein R1 and R2 are the same or different and each represents C1-6 alkyl, C3-8 cycloalkyl, et al; R3a, R3b, and R4 are the same or different and each represents hydrogen, C1-6 alkyl, et al; X represents —N—, —CH—, et al; Y, represents a single bond, C1-3 alkylene, et al; Y2 represents C1-4 alkylene, oxy(C1-4 alkylene), et al; Ar1 represents a monocyclic aromatic carbocyclic group, monocyclic aromatic heterocyclic group, et al; and Ar2 represents a 5- or 6-membered aromatic carbocyclic group, aromatic heterocyclic group, et al]. This compound functions as a melanin-concentrating hormone receptor antagonist and is useful as, e.g., a therapeutic agent for obesity, et al.Type: ApplicationFiled: September 30, 2005Publication date: December 27, 2007Inventors: Takao Suzuki, Minoru Moriya, Shunji Sakuraba, Sayaka Mizutani, Hisashi Iwaasa, Akio Kanatani
-
Patent number: 7304072Abstract: Compounds represented by the general formula (I) wherein Ar1 represents an aryl or heteroaryl which may be substituted; n represents 0 or 1; T, U, V and W each independently represent a nitrogen atom or a methine group which may have a substituent selected from the group consisting of halogen, lower alkyl, hydroxy and lower alkoxy, wherein at least two of which represent said methine group; X represents methine, hydroxy substituted methine or nitrogen atom; Y represents an imino which may be substituted with lower alkyl, or oxygen; and a salt, ester or N-oxide derivative thereof. The compounds exhibit NPY antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders, central nervous system disorders, metabolic diseases, sexual and reproductive dysfunctions, gastro-intestinal disorders, respiratory disorders, inflammation or glaucoma, and the like.Type: GrantFiled: August 23, 2004Date of Patent: December 4, 2007Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Takehiro Fukami, Akio Kanatani, Akane Ishihara, Yasuyuki Ishii, Toshiyuki Takahashi, Yuji Haga, Toshihiro Sakamoto, Takahiro Itoh, Masato Chiba